Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INF904 first-in-human single and multiple ascending dose study in healthy volunteers
NL-OMON53655Phase 1Completed
- Sponsor
- InflaRx
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of izicopan in inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (6 arms), sponsored by InflaRx. Primary endpoints: Adverse events, Physical examination and 4 more. Started Oct 2022; status: completed.
02
Drugs
izicopan
03
Conditions
inflammatory bowel disease (IBD)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON53655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53655.